A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Clinical trial NCT03934567 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03934567
- Sponsor
- Xynomic Pharmaceuticals, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-22
- Primary completion
- 2025-01-29
- Enrollment
- 87
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.